Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.50 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.48 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | BRD4 | O60885 | 2/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HK1 | P19367 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10918416 | 0.98 | AHR (0.48) | AHRPDK2CYP11B1CYP11B2NPC1 | |
| SCHEMBL30695792 | 0.85 | CYP11B1 (0.44) | AHRPDK2CYP11B1CYP11B2NPC1 | |
| SCHEMBL8872240 | 0.82 | MAOA (0.50) | AHRPDK2NPC1MAPK13MAPK12 | |
| SCHEMBL885250 | 0.80 | NPC1 (0.55) | AHRPDK2CYP11B1CYP11B2NPC1 | |
| SCHEMBL4398875 | 0.80 | KMT2A (0.39) | AHRPDK2CYP11B1CYP11B2NPC1 | |
| Valeric Acid SCHEMBL5165826 | 0.80 | ALDH1A1 (0.43) | AHRPDK2CYP11B1CYP11B2MAPK1 | |
| Oxindole SCHEMBL11199955 | 0.78 | AHR (0.70) | AHRPDK2NPC1MAPK13MAPK12 | |
| SCHEMBL2008333 | 0.77 | ALOX5 (0.54) | AHRPDK2NPC1MAPK13MAPK12 | |
| SCHEMBL3993853 | 0.75 | MAPT (0.50) | AHRPDK2NPC1MAPK13MAPK12 | |
| SCHEMBL10061675 | 0.75 | MAPT (0.41) | AHRPDK2NPC1MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 642 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3768675-B1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORP (KR) | 2026-04-01 | — | — | EP | claimed |
| US-20240409531-A1 | BENZOXAZINONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS | MERCK SHARP & DOHME LLC (US) | 2024-12-12 | — | — | US | claimed |
| CN-118894816-A | 3, 3-Difluoroallylamine or salt thereof and pharmaceutical composition comprising the same | 柳韩洋行 | 2024-11-05 | — | — | CN | claimed |
| CN-113330001-B | 3, 3-Difluoroallylamine or salt thereof and pharmaceutical composition comprising the same | 柳韩洋行 | 2024-07-02 | — | — | CN | claimed |
| CN-111886233-B | Triazolone derivatives or salts thereof and pharmaceutical compositions containing the same | 柳韩洋行 | 2024-01-02 | — | — | CN | claimed |
| US-11780830-B2 | Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2023-10-10 | — | — | US | claimed |
| US-11518766-B2 | Tricyclic compound, preparation method therefor and use thereof | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD. (CN) | 2022-12-06 | — | — | US | claimed |
| CN-110204506-B | CO 2 Synthesis of 1,4-dihydro-2H-3,1-benzoxazine-2-one derivative as C1 source | 常州大学 | 2022-10-28 | — | — | CN | claimed |
| EP-4076459-A1 | PRMT5 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2022-10-26 | — | — | EP | claimed |
| US-20220251095-A1 | TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangxi Jemincare Group Co., Ltd. (CN) | 2022-08-11 | — | — | US | claimed |
| CN-1179753-C | Contraceptive compositions contaiing antiprogesting and progestinic | — | 2004-12-15 | — | — | CN | claimed |
| WO-2004074273-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-09-02 | — | — | WO | claimed |
| US-20040122000-A1 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED. | 2004-06-24 | — | — | US | claimed |
| US-6194391-B1 | CS-87 (TITLE COMPOUND) INDUCES A TRANSIENT MUTATION IN HIV-1 AT THE 70TH CODON OF THE REVERSE TRANSCRIPTASE REGION OF THE VIRUS; ADMINISTERING TO A HUMAN IN NEED OF THERAPY WITH A DRUG THAT INDUCES A MUTATION IN HIV-1 AT ANOTHER LOCATION | EMORY UNIVERSITY | 2001-02-27 | — | — | US | claimed |
| EP-0968197-A1 | EFFICIENT SYNTHESIS OF A 1,4-DIHYDRO-2H-3,1-BENZOXAZIN-2-ONE | Merck & Co., Inc. (US) | 2000-01-05 | — | — | EP | claimed |
| US-5922864-A | ADDING AN ARYL CHLOROFORMATE TO A STIRRING MIXTURE OF AN AMINO ALCOHOL DERIVATIVE IN AN ORGANIC SOLVENT WITH A BASE TO PRODUCE CARBAMATE INTERMEDIATE, STIRRING, QUENCHING WITH WATER OR AQUEOUS BASE, STIRRING UNTIL CYCLIZATION, ISOLATING | MERCK & CO., INC. (US) | 1999-07-13 | — | — | US | claimed |
| WO-1998034928-A1 | EFFICIENT SYNTHESIS OF A 1,4-DIHYDRO-2H-3,1-BENZOXAZIN-2-ONE | MERCK & CO., INC. (US) | 1998-08-13 | — | — | WO | claimed |
| US-5171851-A | Cardiac stimulant | DONG-A PHARM. CO., LTD. (KR) | 1992-12-15 | — | — | US | claimed |
| EP-0510235-A1 | Novel benzoxazine or benzothiazine derivatives and process for the preparation of the same | DONG-A PHARM. CO., LTD. (KR) | 1992-10-28 | — | — | EP | claimed |
| US-4301283-A | BY TREATING A 2-CARBAMOYL-BENZYL ALCOHOL WITH A HYPOHALITE IN THE PRESENCE OF A PHASE TRANSFER CATALYST | STERLING DRUG INC. (US) | 1981-11-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240409531-A1 | BENZOXAZINONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS | NFATC1, ACIN1, GZMB | AHR 1423/4885PDK2 998/4885CYP11B1 709/4885 |
| US-11780830-B2 | Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same | SLC10A1, VAT1, LIPC | AHR 3076/4885PDK2 807/4885CYP11B1 449/4885 |
| US-20040122000-A1 | Inhibitors of aspartyl protease | SPINT2, DNPEP, PRSS1 | AHR 4020/4885PDK2 2190/4885CYP11B1 4345/4885 |
| US-11518766-B2 | Tricyclic compound, preparation method therefor and use thereof | TFPI, TFPI2, F11 | AHR 2220/4885PDK2 1585/4885CYP11B1 111/4885 |
| US-20220251095-A1 | TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | TFPI, TFPI2, F11 | AHR 2220/4885PDK2 1585/4885CYP11B1 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.